Christopher S. Seet

This study shows that engineered NK cells with a CD4-based CAR delay HIV rebound and alter the reservoir's composition in humanized mice.

This study shows that locally produced complement factor B in the gut reduces colitis, highlighting its role in mucosal immunity.

The paper shows that T cells engineered with IL-9R have better tissue infiltration, stemness, and anti-tumor activity compared to those with an orthogonal IL-9 receptor, due to stronger and more specific JAK/STAT signaling.

This study generates TCR-null CAR T cells from iPSCs by controlling CAR signaling stages, resulting in naive-like cells with enhanced cytotoxicity.

IRIS identifies cancer immunotherapy targets from alternative splicing using transcriptomics data and validates them with patient T cells.